Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of radioguided occult lesion localization (ROLL) versus wire-guided localization (WGL) in breast conserving surgery for nonpalpable breast cancer: results from a randomized controlled multicenter trial.
Postma EL, Koffijberg H, Verkooijen HM, Witkamp AJ, van den Bosch MA, van Hillegersberg R. Postma EL, et al. Among authors: van hillegersberg r, van den bosch ma. Ann Surg Oncol. 2013 Jul;20(7):2219-26. doi: 10.1245/s10434-013-2888-7. Epub 2013 Feb 23. Ann Surg Oncol. 2013. PMID: 23435568 Clinical Trial.
Localization of nonpalpable breast lesions.
Postma EL, Witkamp AJ, van den Bosch MA, Verkooijen HM, van Hillegersberg R. Postma EL, et al. Among authors: van hillegersberg r, van den bosch ma. Expert Rev Anticancer Ther. 2011 Aug;11(8):1295-302. doi: 10.1586/era.11.116. Expert Rev Anticancer Ther. 2011. PMID: 21916583 Review.
Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial.
Postma EL, Verkooijen HM, van Esser S, Hobbelink MG, van der Schelling GP, Koelemij R, Witkamp AJ, Contant C, van Diest PJ, Willems SM, Borel Rinkes IH, van den Bosch MA, Mali WP, van Hillegersberg R; ROLL study group. Postma EL, et al. Among authors: van der schelling gp, van hillegersberg r, van den bosch ma, van esser s, van diest pj. Breast Cancer Res Treat. 2012 Nov;136(2):469-78. doi: 10.1007/s10549-012-2225-z. Epub 2012 Sep 30. Breast Cancer Res Treat. 2012. PMID: 23053639 Clinical Trial.
MRI-guided ablation of breast cancer: where do we stand today?
Postma EL, van Hillegersberg R, Daniel BL, Merckel LG, Verkooijen HM, van den Bosch MA. Postma EL, et al. Among authors: van hillegersberg r, van den bosch ma. J Magn Reson Imaging. 2011 Aug;34(2):254-61. doi: 10.1002/jmri.22599. J Magn Reson Imaging. 2011. PMID: 21780220 Review.
Feasibility of MRI-guided large-core-needle biopsy of suspiscious breast lesions at 3 T.
Peters NH, Meeuwis C, Bakker CJ, Mali WP, Fernandez-Gallardo AM, van Hillegersberg R, Schipper ME, van den Bosch MA. Peters NH, et al. Among authors: van hillegersberg r, van den bosch ma. Eur Radiol. 2009 Jul;19(7):1639-44. doi: 10.1007/s00330-009-1310-0. Epub 2009 Feb 13. Eur Radiol. 2009. PMID: 19214520 Free PMC article.
Prediction of positive resection margins in patients with non-palpable breast cancer.
Barentsz MW, Postma EL, van Dalen T, van den Bosch MA, Miao H, Gobardhan PD, van den Hout LE, Pijnappel RM, Witkamp AJ, van Diest PJ, van Hillegersberg R, Verkooijen HM. Barentsz MW, et al. Among authors: van den hout le, van hillegersberg r, van den bosch ma, van diest pj, van dalen t. Eur J Surg Oncol. 2015 Jan;41(1):106-12. doi: 10.1016/j.ejso.2014.08.474. Epub 2014 Sep 2. Eur J Surg Oncol. 2015. PMID: 25228054
Discrepancy between routine and expert pathologists' assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment.
Postma EL, Verkooijen HM, van Diest PJ, Willems SM, van den Bosch MA, van Hillegersberg R. Postma EL, et al. Among authors: van hillegersberg r, van den bosch ma, van diest pj. Eur J Pharmacol. 2013 Oct 5;717(1-3):31-5. doi: 10.1016/j.ejphar.2012.12.033. Epub 2013 Mar 30. Eur J Pharmacol. 2013. PMID: 23545360 Clinical Trial.
606 results